Nomosic50 mg

Nomosic is a first-generation antihistamine (piperazine derivative) with established antiemetic and anti-vertigo activity. Its indications are classified below by strength of evidence:

Established/Approved Uses

• Vertigo: Management of vertigo associated with diseases affecting the vestibular system in adults.
• Motion sickness: Prevention and treatment of nausea, vomiting, and dizziness associated with motion sickness (an established over-the-counter use in many markets).

Adjunct/Symptomatic Use

• Symptomatic relief of nausea and vomiting of various causes as an adjunct, used only under medical supervision when the underlying cause has been assessed by a physician.

Nomosic does not treat the underlying cause of vertigo or motion sickness; it only relieves associated symptoms.

Each tablet contains Meclizine Hydrochloride as the active ingredient, commonly available in strengths such as 12.5 mg, 25 mg, or 50 mg, along with pharmaceutically acceptable excipients such as lactose, starch, magnesium stearate, and colorants depending on the manufacturer's formulation.

Nomosic is a piperazine-derivative, first-generation antihistamine that also possesses anticholinergic, central nervous system depressant, and local anesthetic properties. It is chemically distinct from phenothiazine antiemetics and is widely used for its antiemetic and anti-vertigo effects. It is typically formulated as oral tablets, including chewable tablet forms, for once-daily or divided dosing.

Nomosic belongs to the class of first-generation (sedating) H1-antihistamines, specifically the piperazine derivative subclass, and is classified therapeutically as an antiemetic/anti-vertigo agent.

Mechanism of Action

The therapeutic effect of Meclizine Hydrochloride is presumed to result from its central anticholinergic and antihistaminic (H1-receptor antagonist) properties. By blocking H1 receptors and reducing vestibular stimulation of the labyrinth and its central connections, it suppresses nausea, vomiting, and vertigo signals in the medulla, particularly the chemoreceptor trigger zone and vestibular apparatus.

Pharmacokinetics

• Absorption: Onset of action typically occurs within 1 hour of oral administration.
• Peak plasma concentration: Reached at a median of approximately 3 hours (range 1.5–6 hours).
• Duration of action: Approximately 8–24 hours.
• Metabolism: Primarily hepatic, largely via the CYP2D6 enzyme pathway.
• Elimination half-life: Approximately 5–6 hours.

Nomosic is administered orally, with or without food. Tablets may be swallowed whole or, for chewable formulations, chewed thoroughly before swallowing. For motion sickness prevention, it should be taken about 1 hour before the activity expected to cause motion sickness.

Clinically Significant Interactions

• CNS depressants (alcohol, sedatives, hypnotics, opioids, benzodiazepines): Concurrent use with Nomosic may cause additive central nervous system depression, resulting in increased drowsiness and impaired mental/physical alertness. Concomitant use should be avoided or closely monitored.
• Ototoxic drugs (e.g., high-dose aminoglycosides, other ototoxic agents): Nomosic may mask symptoms of ototoxicity (such as tinnitus and dizziness), potentially delaying detection of drug-induced ear damage.
• Other anticholinergic drugs: Additive anticholinergic effects (dry mouth, blurred vision, urinary retention, constipation) may occur when combined with other anticholinergic agents.
• CYP2D6 inhibitors/substrates: Since Nomosic undergoes metabolism partly via CYP2D6, concurrent use of strong CYP2D6 inhibitors may theoretically alter its plasma levels; clinical significance is generally limited but caution is advised.

The most commonly reported adverse effect of Nomosic is drowsiness, which may impair the ability to drive or operate machinery, especially when combined with alcohol or other CNS depressants.

Common Side Effects

• Drowsiness/sedation (most common)
• Dry mouth
• Blurred vision
• Headache
• Fatigue

Less Common/Rare Side Effects

• Urinary retention (anticholinergic effect)
• Constipation
• Tachycardia
• Hypersensitivity/allergic reactions, including rare anaphylactic reactions

Pregnancy: Available human data with Nomosic have not shown a clear increased risk of major birth defects; however, animal reproduction studies have shown fetal malformations at doses substantially higher than the maximum recommended human dose. As with any medication in pregnancy, Nomosic should be used during pregnancy only if clearly needed and if the potential benefit justifies the potential risk to the fetus; a physician should always be consulted before use in pregnancy.

Lactation: It is not known whether Nomosic is excreted in human breast milk. Because many drugs are excreted in breast milk and sedating antihistamines may reduce milk supply or sedate the infant, caution is advised and a physician should be consulted before use while breastfeeding.

Nomosic should be used with caution in the following situations:

• Drowsiness/sedation: Patients should be cautioned against driving, operating heavy machinery, or engaging in hazardous activities until they know how this medicine affects them; concurrent alcohol use should be avoided (see Interactions).
• Narrow-angle glaucoma: Anticholinergic effects may increase intraocular pressure; use with caution.
• Bladder neck obstruction/benign prostatic hyperplasia (BPH): Anticholinergic effects may worsen urinary retention.
• Asthma/chronic obstructive pulmonary disease (COPD): Anticholinergic effects may thicken bronchial secretions, potentially worsening respiratory conditions.
• Elderly patients: Increased risk of confusion, dizziness, sedation, and falls; use the lowest effective dose (see Use in Special Populations).
• Diagnostic interference: May mask symptoms of ototoxicity or obscure diagnosis in cases of appendicitis or intestinal obstruction because it can suppress nausea/vomiting that would otherwise signal these conditions.

Overdose of Nomosic may cause excessive drowsiness, dizziness, hypotension, dry mouth, blurred vision, and in severe cases, hallucinations, convulsions, or respiratory depression, particularly in young children. In case of a suspected overdose, seek immediate medical attention or contact a poison control center/emergency services right away. Do not attempt home treatment; management should be conducted under medical supervision, generally with supportive and symptomatic care.

Store at room temperature (below 30°C), away from light and moisture. Keep out of reach of children.

Pediatric Use

Safety and efficacy of Nomosic have not been established in children under 12 years of age. It is generally not recommended for use in this age group due to limited data.

Geriatric Use

Elderly patients may be more sensitive to the anticholinergic and sedative effects of Nomosic, with increased risk of confusion, dizziness, and falls. Treatment should generally begin at the lower end of the dosing range, with careful monitoring.

Renal/Hepatic Impairment

Specific dose adjustment data are limited; use with caution and under medical supervision in patients with significant hepatic or renal impairment, as drug clearance may be reduced.

For motion sickness, Nomosic is generally used short-term, on an as-needed basis for the duration of travel. For vertigo, duration of treatment should be determined by the prescribing physician based on clinical response and the underlying cause, with periodic reassessment.

First-generation antihistamine; piperazine derivative; antiemetic/anti-vertigo agent.

Meclizine Hydrochloride exerts its therapeutic effect primarily through antagonism of central and peripheral histamine H1 receptors, along with anticholinergic activity, which together reduce vestibular excitability and suppress the vomiting center's response to labyrinthine stimulation.

Nomosic is generally not recommended for children under 12 years of age, as safety and efficacy have not been established in this population. Use in adolescents 12 years and older for motion sickness follows adult-equivalent dosing under medical or product-label guidance. Any pediatric use should be under the direct supervision of a physician.